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Abstract 
     Discussion of fertility-sparing treatment is an important part of pretreatment counseling 
for young patients with early epithelial ovarian cancer.  As a result of late childbearing 
nowadays, fertility preservation has become a major issue in ovarian cancer patients.  The 
purpose of this review is to update current knowledge on fertility-sparing treatment for early 
stage epithelial ovarian cancer, which may be useful for pretreatment counseling for 
reproductive-age patients. The multicenter study data on the fertility-sparing treatment 
published by Japan Clinical Oncology Group (JCOG) in 2010 confirmed that fertility-sparing 
surgery is a safe treatment for stage IA patients with non-clear cell histology and grade 1 or 2 
and suggested that stage IA patients with clear cell histology and stage IC patients with 
non-clear cell histology and grade 1 or 2 can be candidates for fertility-sparing surgery 
followed by adjuvant chemotherapy. In the current review, we added the recent case series 
and review, and discussed the fertility-sparing treatment on young patients with early 
epithelial ovarian cancer.   We need not to change the proposal by the JCOG study, but we 
should wait the results of an ongoing prospective study to strongly recommend the proposal 
of the JCOG study. 
    
Mini-abstract  
     Fertility-sparing surgery (FSS) with optimal staging followed by adjuvant 
chemotherapy can be considered for patients with stage IC non-clear cell carcinoma (CCC) 
and grade 1 or 2 disease and patients with stage IA CCC, though FSS with optimal staging not 
followed by adjuvant chemotherapy is recommended for stage IA non-CCC and grade 1 or 2 
disease. FSS cannot be recommended for patients with stage IC CCC or stage I non-CCC and 
grade 3 disease. 
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INTRODUCTION 
     Preservation of fertility is an important issue for reproductive-age patients with 
epithelial ovarian cancer. The first reports of fertility-sparing surgery (FSS) for epithelial 
ovarian cancer started to appear in the 1960-70s (Munnell EW, Is conservative therapy ever 
justified in stage IA cancer of the ovary? Am J Obstet Gynecol 103; 641, 1969).  However, 
only fewer than 60 patients had been reported in each case series undergoing FSS for stage I 
EPITHELIAL OVARIAN CANCER until the Gynecologic Cancer Study Group of the Japan 
Clinical Oncology Group (JCOG) carried out a multicenter study of 30 institutions (the 
JCOG-FSS study) in 2010, which analyzed 211 cases of FSS for stage I EPITHELIAL 
OVARIAN CANCER including 30 patients with clear cell carcinoma (CCC) (1).  The 
JCOG-FSS study confirm that fertility-sparing surgery is a safe treatment for stage IA patients 
with non-CCC and grade 1 or 2 (G1/G2) and suggest that stage IA patients with CCC and 
stage IC patients with non-CCC and G1/G2 disease can be candidates for FSS followed by 
adjuvant chemotherapy.  After the publication of the JCOG-FSS study, Hu et al. summarized 
94 cases in 2011 (2), Fruscio et al. 237 cases in 2013 (3), and Kajiyama et al. 94 cases in 
2014 (4).  The addition of these cases has now enabled a more detailed discussion regarding 
fertility-sparing treatment in reproductive age patients with early stage ovarian cancer. The 
pooled analyses using Medline database by Nam et al. (5) and Zapardiel et al. (6) supported 
the conclusion of JCOG-FSS study.    
     In Japan, JCOG launched a non-randomized confirmatory study of fertility-sparing 
surgery for patients with epithelial ovarian cancer (JCOG1203) in 2014 (7).  This is a 
prospective study for confirming the conclusion of the JCOG-FSS study that FSS with 
optimal staging followed by adjuvant chemotherapy can be considered for stage IA patients 
with CCC and stage IC patients with non-CCC and G1/G2 disease.  Since this FSS is an 
experimental treatment, patients are enrolled preoperatively before stage of disease, 
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histological type and grade are determined.  For this reason, subjects are divided by their 
final pathology results into a primary analysis group (stage IA patients with CCC or stage IC 
patients with non-CCC and G1/G2 disease) and a non-primary analysis group comprising 
patients other than these.  Both groups except patients with benign disease are followed up 
for at least five years. The primary endpoint for the primary analysis group is five-year 
survival rate.  
     The purpose of this review is to update current knowledge on FSS for early stage 
epithelial ovarian cancer, which may be useful for pretreatment counseling for 
reproductive-age patients. The search was restricted to articles describing relevant clinical and 
histologic factors such as stage of disease, surgical procedures, histological type and grade, 
site of recurrence, and survival. Fertility outcomes after FSS are not discussed in this review, 
because the good fertility outcomes have already been addressed in two previous reviews 
(5,6). 
 
Evaluation of Survival and Relapse after Conservative Management of Ovarian Cancer  
     The conservative management should meet one of the following two requirements in 
survival. One requirement is an absolutely good prognosis after fertility-sparing treatment is 
performed, for example, which exceed 95% in five-year survival rate.  Another requirement 
may be that fertility-sparing treatment is not inferior to radical treatment in survival 
irrespective of survival rates, because fertility-sparing treatment has an obvious advantage 
that the patient can bear children. However, there are no studies comparing the survival 
between fertility-sparing and radical treatments in early ovarian cancer. We can only compare 
the survival rate of fertility-sparing treatment in one case series with that of radical treatment 
in another case series. 
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     The prognosis for patients with recurrence in the contralateral or residual ovary alone 
after FSS is much better than for patients with other patterns of recurrence.  A review of 
seven papers (1,3, 8–12) that include clear details of patterns of recurrence and outcomes 
showed that the disease-free survival rate after salvage therapy was 82.1% (23/28) for patients 
with recurrence in the oppposite ovary alone, compared with 19.2% (10/52) for those with 
other patterns of recurrence (Table 1).  Other studies have also found that patients with 
recurrence in the contralateral ovary alone have better outcomes (13,14).  Recurrence pattern 
is an important factor that should be taken into account when considering the patient selection 
for FSS. 
Conservative Management of Stage I Ovarian Cancer by Substage, Histology and Grade in 
Young Women 
 
Stage IA, non-CCC, G1 
     FSS is recommended for patients with stage IA non-CCC and G1 disease. When data 
from ten papers containing sufficient information about patients with sIA non-CCC and G1 
disease (1, 3, 9–12, 15–18) were combined, the recurrence-free rate was 93.4% (282/302), 
and the survival rate was 98.0% (296/302) (Table 2).  FSS not followed by adjuvant 
chemotherapy is adequate treatment for patients in this group because the absolute prognosis 
is good.   
Of the patients in the above ten case series, 12 developed recurrent mucinous 
adenocarcinoma after a median time of 17.5 months (range 9–172 months); the pattern of 
recurrence was in the contralateral ovary alone in 4 patients and elsewhere in 8.  For the 8 
patients with serous or endometrioid adenocarcinoma, the median time to recurrence was 62 
months (range 23–83 months), and the recurrence occurred in the contralateral ovary alone in 
7 patients and elsewhere in 1.  The time to recurrence was shorter and recurrence was 
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common in locations other than the contralateral ovary in patients with mucinous 
adenocarcinoma. One reason may be that components consisting of anaplastic carcinoma or 
sarcoma are sometimes present in mucinous tumors with mural nodules, and this is known to 
be associated with a poor prognosis (19,10).  Another reason may be that mucinous 
adenocarcinoma has been found to be metastatic in 70.3% (21) or 77% (22) of cases, and 
tumors removed during FSS may in fact have been metastatic carcinomas.  These two points 
must be borne in mind when considering FSS for mucinous adenocarcinoma.   
One study found that 24% of cases of ovarian cancer were genetic (23), and in such 
cases, it is quite possible that a new ovarian cancer may develop in the remaining ovary and 
tube.    Taking a detailed family history may be important when considering FSS in ovarian 
cancer, not only for patients with stage IA non-CCC and G1 disease.  If there is a family 
history of ovarian cancer, then greater caution may be required when choosing FSS. And it 
may be appropriate to consider the removal of the residual ovary and tube at the point when 
the patient no longer desires to have children.  
 Endometrioid and clear cell adenocarcinomas are known to develop from ovarian 
endometriosis (24, 25), and de novo carcinogenesis may be conceivable in these hystologies. 
It is vital to ensure that no endometriotic lesions are left behind in the contralateral ovary 
during FSS. 
 
Stage IA, non-CCC, G2 
     FSS is recommended for patients with stage IA non-CCC and G2 disease.  When data 
from nine papers containing sufficient information about patients with stage IA non-CCC and 
G2 disease (1, 3, 9–12, 16–18) were combined, although the recurrence-free rate was 
somewhat low, at 87.5% (70/80), the survival rate was high, at 95% (76/80) (Table 3).  One 
patient was alive with cancer, and for one the prognosis was unknown, but even if these two 
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individuals were to be added to the number of deaths, the survival rate would still exceed 90%, 
at 92.5%. FSS may therefore be actively recommended to patients in this group, because the 
prognosis is good. 
     Although there is a global consensus on the histological types of ovarian cancer, there is 
as yet no common grading system.  The diagnosis of G2 disease may thus vary among 
institutions or pathologists.  In fact, the frequency of G2 disease recorded in studies of FSS 
differed markedly; 7.1% (1), 8.5% (9), 14.9% (4), 17.3% (11) 25.0% (12), and 28.7% (3).  In 
the case of serous adenocarcinoma (26, 27) and endometrioid adenocarcinoma (28), the 
pathologists can choose from the several different grading systems that have been so far 
proposed.  When grades are divided into two groups and compared, it is easy to imagine that 
the evaluation of G2 will differ depending on whether the division is between G1/G2 and G3 
(1, 3) or between G1 and G2/3 (4, 12).  The former two studies concluded that FSS may be 
recommended for patients with G2 disease, whereas the latter two found that multivariate 
analysis identified G2/G3 as an independent factor for significantly poorer prognosis 
compared with G1. 
     The diagnostic criteria for G2 disease in mucinous adenocarcinoma may vary with 
institutions, for which no general grading system has yet been proposed. This difference may 
underlie the high recurrence rates reported by Schilder et al. (11) and Morice et al. (10) on the 
one hand and the lower rates reported by Satoh et al. (1) and Fruscio et al. (3) on the other 
hand.   
 
Stage IA, CCC 
     FSS followed by adjuvant chemotherapy may be considered for patients with stage IA 
CCC.  When data from six papers containing sufficient information about patients with stage 
IA CCC (1,9–11,15,29) were combined, although the recurrence-free rate was somewhat low, 
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at 88.9% (24/27), the survival rate exceeded 90%, at 92.6% (25/27) (Table 4). One patient 
was alive with cancer, and if this individual were to be added to the number of deaths, the 
survival rate would drop to slightly under 90%. Frucio et al. reported that, of 17 patients with 
CCC, recurrence developed in one stage IA patient and one stage IC patient, although the 
details of the staging procedures were not described, and they stated that, despite recurrence 
in the pelvis and abdomen, the stage IA patient was still disease-free 87 months after salvage 
therapy (3).   Kajiyama et al. also reported that, of 17 stage I CCC patients, no stage IA 
patient developed recurrence, although the numbers of patients of each stage I substage were 
not given (4).  The fact that no stage IA patient died in either of these studies suggests that 
the survival rate should exceed 90%, meaning that FSS followed by adjuvant chemotherapy 
may be considered for patients with stage IA CCC. 
     In light of the possibility that these numbers include some patients who did not undergo 
complete surgical staging, particularly those who did not undergo lymph node dissection or 
biopsies, it is quite possible that mortality will be less than 10% if staging is complete.  The 
only one of these six studies to describe lymphadenectomy as included in the surgical 
procedures was that of Anchezar (15), with the others listing biopsy, sampling, or 
lymphadenectomy as options.  The rate of lymph node metastasis in retroperitoneal, stage 
I/II CCC identified by systematic lymphadenectomy has been reported as 29.4% (5/17) (30), 
and complete staging surgery is essential when performing FSS for CCC. 
     Some reports have evaluated CCC as a separate entity without grading it (1,4,29), 
whereas others have included it in G3 disease (3,9–11,15).  The proportion of EPITHELIAL 
OVARIAN CANCER patients with CCC is rising in Japan, and it has recently been found to 
account for around 25% of all cases (31), whereas in North America and Europe, most 
ovarian cancer patients suffer from serous adenocarcinoma, with CCC patients accounting for 
only 1–12% of cases (32).  The low number of cases and the generally poor prognosis for 
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CCC (33,34) suggest that, historically, CCC has probably been included in G3 for the purpose 
of statistical analysis.  If only stage IA is considered, however, the prognosis has been shown 
to be good (33–35), suggesting that CCC should be handled separately from G3 disease. 
 
Stage IC (unilateral disease), non-CCC, G1 
     FSS followed by adjuvant chemotherapy can be considered for patients with stage IC 
non-CCC and G1 disease.  When data from six papers containing sufficient information 
about patients with stage IC non-CCC and G1 disease (1, 3, 9, 10, 15, 36) were combined, 
although the recurrence-free rate was somewhat low, at 84.8% (134/158), the survival rate 
was high, at 94.9% (150/158) (Table 5).  Two patients were alive with cancer, but even if 
these individuals were to be added to the number of deaths, the survival rate would still 
exceed 90%, at 93.7% (148/158).  FSS can thus be recommended for patients in this group, 
because the absolute prognosis is good.  Of the patients with recurrence, for the 8 with 
mucinous adenocarcinoma, the median time to recurrence was 13 months (range 2–43 
months), and the pattern of recurrence was in the contralateral ovary alone in 4 patients and 
elsewhere in 4.  For the 10 patients with recurrence of serous or endometrioid 
adenocarcinoma, the median time to recurrence was 19.5 months (range 3–118 months), and 
the pattern of recurrence was in the contralateral ovary alone in 6 patients and elsewhere in 4. 
 
Stage IC (unilateral disease), non-CCC, G2 
     FSS followed by adjuvant chemotherapy can be considered for patients with stage IC 
non-CCC and G2 disease.  When data from five papers containing sufficient information 
about patients with stage IC non-CCC and G2 disease (1, 3, 9, 11,15) were combined, 
although the recurrence-free rate was somewhat low, at 86.7% (39/45), the survival rate was 
high, at 93.3% (42/45) (Table 6). One patient was alive with cancer, but even if this individual 
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were to be added to the number of deaths, the survival rate would still exceed 90%, at 91.1% 
(41/45).  FSS followed by adjuvant chemotherapy may therefore be considered to patients in 
this group because the absolute prognosis is good. 
 
Stage IC (unilateral disease), CCC 
     FSS cannot be recommended for patients with stage IC CCC.  When data from seven 
papers containing sufficient information about patients with stage IC CCC disease (1,9–
11,15,29,36) were combined, the recurrence-free rate was low, at 77.4% (24/31), although the 
survival rate exceeded 90%, at 90.3% (28/31) (Table 7).  Three patients were alive with 
cancer, however, and if these individuals were to be added to the number of deaths, the 
survival rate would drop below 90%, at 80.6% (25/31).  Frucio et al. also reported that, of 
the 17 CCC patients who developed recurrence, 1 individual who was stage IC developed 
recurrence in the pelvis and died 11 months after salvage therapy (3), and Kajiyama et al. 
reported that, of 17 patients with stage I CCC, 3 stage IC patients died (4).  The inclusion of 
the deaths of stage IC patients from these studies would further decrease the survival rate, and 
the choice of FSS cannot therefore be recommended for patients with stage IC CCC. 
     The five-year disease-specific survival rate for patients with stage IC CCC has been 
reported as 77.3% (34), with a five-year overall survival rate of 60.1% (33) and a three-year 
OVERALL SURVIVAL rate of 85.9% (35).  There are insufficient data to determine 
whether patients with stage IC CCC belong to a group for which the prognosis would be 
similar if radical surgery were performed even if the absolute prognosis itself is poor, but the 
possibility that it may be similar cannot be ruled out.  In the seven papers examined, 5 of the 
7 patients who developed recurrence were stage IC1.  Looking at the two papers that stated 
that patients were stage IC1 CCC (3, 29), the recurrence-free rate was low, at 75% (12/16), 
and although the survival rate was 93.8% (15/16), if 2 patients who were alive with cancer 
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were to be added to the number of deaths, the survival rate would be low, at 81.3% (13/16).  
Studies have found that the prognosis for patients with stage IC CCC is significantly better for 
those who are stage IC1 compared with those who are stage IC2/3 (37), and very recently it 
has been reported that three-year OVERALL SURVIVAL for stage IC1 patients is 96.2%, 
similar to the 93.5% reported for stage IA patients and significantly better than the 71.9% for 
patients who are stage IC2/3 (35).  Although the prognosis for stage IC1 CCC is generally 
good, the fact that it is poor for stage IC1 patients who have undergone FSS suggests that FSS 
cannot be recommended at this point; this is because it has yet to be shown that, even if the 
prognosis is poor, it is similar to that if radical surgery were performed, although the number 
of cases reviewed in this study was small. 
 
Stage IA or IC (unilateral disease), G3 (CCC excluded) 
     FSS cannot be recommended for patients who are stage I and have G3 disease. As 
described above, most of the studies from countries other than Japan have counted CCC as 
G3 disease, but it is possible to identify the number of cases of G3 disease that are not CCC 
from some carefully written papers from overseas (although for papers that included patients 
of stage II and above, we assumed that patients with CCC were only stage I).  When data 
from nine papers containing sufficient information about patients with stage I cancer and G3 
disease (not including those with CCC) (1,3,9,10,12,16,18,38,39) were combined, the 
recurrence-free rate was extremely low for stage I, at 54.1% (20/37), and the survival rate was 
also low, at 67.6% (25/37) (Table 8). One patient was alive with cancer, and if this individual 
were to be added to the number of deaths, the survival rate would be 64.9% (24/37). FSS 
cannot be recommended because the absolute prognosis is poor. 
     Following Frusio et al., we compared this reviewed results with those of the 
ICON1/ACTION analysis (40).  Figure 3 of that paper lists the number of patients with G3 
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disease, including those with CCC, as well as the individual numbers of patients with CCC 
and the numbers of events affecting overall survival, making it possible to calculate the 
survival rate for patients with non-CCC G3 disease by subtracting the number of CCC 
patients from the number of patients with G3 disease, including those with CCC.  Almost 
80% of the stage I patients with G3 disease described in the nine papers who underwent FSS 
and developed recurrence had been treated with chemotherapy, and they may appropriately be 
compared with the patients who underwent chemotherapy in the ICON1/ACTION analysis.  
A comparison with the 71 chemotherapy patients in the ICON1/ACTION analysis with G3 
disease (non-CCC) showed that 13 events occurred for a survival rate of 81.7%, far higher 
than the survival rate for the patients with G3 disease who underwent FSS; these cannot be 
described as similar results.  FSS may thus lower the survival rate for patients with stage I 
non-CCC and G3 disease, and even from the standpoint that it may be possible to perform 
FSS if the patient belongs to a group for which the prognosis would be similar if radical 
surgery were performed even if the absolute prognosis itself is poor, FSS cannot be 
recommended for patients with G3 disease.  Among the 79 patients who did not undergo 
chemotherapy, there were 25 events, for a survival rate of 68.4%. 
 
Stage IB or IC (bilateral disease), G1/2 
     Very few patients who are stage IB or IC with cancer of both ovaries underwent FSS, 
and the available data are therefore limited.  Satoh et al. (1) enrolled two stage IB patients 
and two who were stage IC with bilateral ovarian disease, but both groups were excluded 
from their analysis because the follow-up period was less than 60 months; however, at the 
time of the study, none of those four patients had developed recurrence (unpublished data).  
Kajiyama et al. reported that the only patient in their study who was stage IB/IC developed 
recurrence of highly differentiated serous adenocarcinoma; although the patient had 
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undergone adnexectomy of the affected side and wedge resection of the contralateral side 
followed by platinum-based chemotherapy, the cancer recurred after 138.9 months, and the 
patient died after 195.7 months (8).  At this point, there is no solid evidence that FSS can be 
selected in patients with stage IB or IC (bilateral disease) irrespective of histologies and 
grades. And we feel great hesitation about preserving a part of the contralateral ovary in 
which the cancer has recurred or metastasized. 
 
Conclusion 
     FSS with optimal staging followed by adjuvant chemotherapy can be considered for 
patients with stage IC non-CCC and G1/2 disease and patients with stage IA CCC, though 
FSS with optimal staging not followed by adjuvant chemotherapy is recommended for stage 
IA non-CCC and G1/2 disease. FSS cannot be recommended for patients with stage IC CCC 
because the absolute prognosis is poor.  FSS is not recommended for patients with stage 
IA/C non-CCC and G3 disease because it may result in a poorer prognosis in comparison with 
that of patients who undergo radical treatment. Since there is insufficient information to reach 
a judgment in the case of patients with stage IB/IC (bilateral ovarian involvement), we cannot 
recommend FSS for these patients. 
     All of the studies of FSS for epithelial ovarian cancer patients that were evaluated in the 
present review were retrospective investigations.  The quality of the data is therefore limited.  
This point must be fully borne in mind when dealing with individual patients. 
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Author (year) n Recurrence n
NED AWD DOD NED AWD DOD
Fruscio (2013) 237 27 12 1 0 3 0 11
Kajiyama (2010) 60 8 0 1 1 1 0 5
Satoh (2010) 211 18 5 0 0 3 5 5
Park (2008) 59 9 1 0 0 1 3 4
Morice (2005) 33 9 2 0 2 2 2 1
Schilder (2002) 52 5 3 0 0 0 0 2
Zanetta (1997) 56 5 1 0 0 0 1 3
isolated ovarian recurrence extraovarian recurrence
Status
Table 1. Oncologic outcomes of stage I patients  with isolated ovary recurrence or with extraovarian recurrence
n, number; NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease.
82.1% (23/28) 19.2% (10/52)Rate of disease free survival after salvage   
Author (year) n Recurrence n Histology Recurrence sites TTR (months） Status FAR (months)
Fruscio (2013) 84 7 Endometrioid contralateral ovary alone 172 NED 46
Mucinous contralateral ovary alone 19 NED 106
Serous contralateral ovary alone 77 NED 56
Serous homolateral ovary alone 23 NED 46
Serous homolateral ovary alone 61 NED 136
Mucinous pelvis 11 DOD 43
Mucinous pelvis-abdomen 38 DOD 5
Satoh (2010) 95 5 Mucinous contralateral ovary alone 83 NED 119
Serous contralateral ovary alone 52 NED 164
Mucinous peritoneum 70 NED 149
Mucinous abdominal wall 14 AWD 39
Mucinous lung 73 DOD 34
Anchezar (2009) 11 2 Endometrioid peritoneal carcinomatosis 63 NED 15
Mucinous lung, liver, abdomen 7 DOD 9
Park (2008) 29 1 Mucinous contralateral ovary alone 33 NED 20
Borgfeldt (2007) 9 0
Morice (2005) 13 2 Mucinous contralateral ovary alone 16 NED 12
Mucinous bone, subcutaneous 7 DOD 40
Colombo (2005) 4 0
Schilder(2002) 33 2 Serous contralateral ovary alone 69 NED 14
Mucinous pelvis-abdomen 9 DOD 4
Zanetta (1997)
Colombo (1994)
24 1 Serous contralateral ovary alone 44 NED NR
Total 302 20 ovary alone: 11, others: 9
Table 2. Oncologic outcomes after fertility-sparing surgery in patients with stage IA non-clear cell  carcinoma grade 1
n, number; TTR, time to recurrence; FAR, follow-up after recurrence; NED, no evidence of disease; AWD, alive with disease;
DOD, dead of disease; NR, not reported.
NED: 13, AWD: 1, DOD: 6
Author (year) n Recurrence n Histology Recurrence sites TTR (months） Status FAR (months)
Fruscio (2013) 31 2 Endometrioid pelvis 50 NED 77
Mucinous pelvis-abdomen 20 DOD 21
Satoh (2010) 13 0
Park (2008) 3 0
Borgfeldt (2007) 1 0
Morice (2005) 14 4 Mixed contralateral ovary alone 12 NED 120
Endometrioid contralateral ovary,  peritoneum 14 NED 44
Mucinous contralateral ovary alone 24 Unknown -
Mucinous contralateral ovary alone 2 DOD 54
Colombo (2005) 4 0
Schilder(2002) 6 2 Endometrioid contralateral ovary alone 13 NED 40
Mucinous lung 78 DOD 19
8 2 Endometrioid spleen 20 AWD NR
Endometrioid brain 8 DOD NR
Total 80 10 ovary alone: 4, others: 6
Table 3. Oncologic outcomes after fertility-sparing surgery in patients with stage IA non-clear cell  carcinoma grade 2
n, number; TTR, time to recurrence; FAR, follow-up after recurrence; NED, no evidence of disease; AWD, alive with disease;
DOD, dead of disease; NR, not reported.
Zanetta (1997)
Colombo (1994)
NED: 4, AWD: 1, DOD: 4
Author (year) n Recurrence n Recurrence sites TTR (months） Status FAR (months)
Satoh (2010) 15 0
Anchezar (2009) 1 0
Kajiyama (2008) 4 0
Park (2008) 2 2 pelvic peritoneum 11 DOD 23
contralateral ovary, liver 9 DOD 20
Morice (2005) 2 1 para-aortic LNs, liver 16 AWD 12
Schilder(2002) 3 0
Total 27 3 ovary alone: 0, others: 3
Table 4. Oncologic outcomes after fertility-sparing surgery in patients with stage IA clear cell  carcinoma
n, number; TTR, time to recurrence; FAR, follow-up after recurrence;  AWD, alive with disease; DOD, dead of
disease; LNs, lymph nodes.
AWD: 1, DOD: 2
Author (year) n Recurrence n Histology Recurrence sites TTR (months） Status FAR (months)
Fruscio (2013) 54 6 Endometrioid homolateral ovary alone 14 NED 14
Mucinous contralateral ovary alone 25 NED 86
Serous contralateral ovary alone 118 NED 76
Serous contralateral ovary alone 44 NED 193
Serous contralateral ovary alone 19 AWD 5
Serous homolateral ovary alone 45 DOD 56
Kashima (2013) 14 4 Mucinous contralateral ovary alone 14 NED 114
Mucinous pelvis lymph nodes 23 DOD 43
Mucinous contralateral ovary, pelvis 7 DOD 10
Serous brain 19 DOD 30
Satoh (2010) 65 5 Endometrioid contralateral ovary alone 7 NED 45
Mucinous contralateral ovary alone 43 NED 16
Mucinous peritoneum 8 AWD 18
Endometrioid liver 20 DOD 6
Serous peritoneum 3 DOD 22
Anchezar (2009) 3 0
Park (2008) 15 1 Mucinous peritoneum, lung 12 DOD 19
Morice (2005) 2 2 Serous contralateral ovary, peritoneum 44 NED NR
Mucinous contralateral ovary alone 2 DOD 52
Total 158 18 ovary alone: 10, others: 8
Table 5. Oncologic outcomes after fertility-sparing surgery in patients with stage IC non-clear cell  carcinoma grade 1
n, number; TTR, time to recurrence; FAR, follow-up after recurrence; NED, no evidence of disease; AWD, alive with disease;
DOD, dead of disease; NR, not reported.
NED: 8, AWD: 2, DOD:8
Author (year) n Recurrence n Histology Recurrence sites TTR (months） Status FAR (months)
Fruscio (2013) 37 4 Endometrioid homolateral ovary alone 169 NED 2
Mucinous pelvis-abdomen 25 DOD 13
Serous pelvis-abdomen 10 DOD 13
Serous skin 48 DOD 9
Satoh (2010) 2 0
Anchezar (2009) 1 0
Park (2008) 2 1 Mucinous contralateral ovary, pelvis-abdomen, LNs 11 AWD 16
Schilder(2002) 3 1 Mixed* contralateral ovary alone 8 NED 10
Total 45 6 ovary alone: 2, others: 4
Table 6. Oncologic outcomes after fertility-sparing surgery in patients with stage IC non-clear cell  carcinoma grade 2
n, number; TTR, time to recurrence; FAR, follow-up after recurrence; NED, no evidence of disease; AWD, alive with disease; DOD, dead of
disease; AWD, alive with disease. * serous and endometrioid
NED: 2, AWD: 1, DOD: 3
Author (year) n Recurrence n Recurrence sites TTR (months） Status FAR (months)
Kashima (2013) 4 1 pelviic LNs 15 DOD 93
Satoh (2010) 15 5 contralateral ovary alone 21 NED 124
para-aortic LNs 15 AWD 86
contralateral ovary, ascites, peritoneum 11 DOD 19
liver 46 AWD 8
contralateral ovary, pelvic LNs, peritoneum 21 AWD 29
Anchezar (2009) 1 0
Kajiyama (2008) 6 1 brain, abdominal wall 20 DOD 17
Park (2008) 2 0
Morice (2005) 1 0
Schilder (2002) 2 0
Total 31 7 ovary alone: 1, others: 6
Table 7. Oncologic outcomes after fertility-sparing surgery in patients with stage IC clear cell  carcinoma
n, number; TTR, time to recurrence; FAR, follow-up after recurrence; LNs, lynph nodes; NED, no evidence of disease;
AWD, alive with disease; DOD, dead of disease; AWD, alive with disease.
NED: 1, AWD:3, DOD: 3
Author (year) n IA/IC Recurrence n IA/IC Histology CT  Recurrence sites TTR (months） Status FAR (months)
Fruscio (2013) 12 NR 5 IC Serous yes LNs 65 NED 143
IA Endometrioid yes pelvis-abdomen 40 DOD 13
IA Mucinous no pelvis-abdomen 7 DOD 8
IA Mucinous yes lung 9 DOD 4
IA Endometrioid yes brain 7 DOD 2
Kajiyama (2011) 4 NR 2 NR NR NR NR NR DOD NR
NR NR NR NR NR DOD NR
Satoh (2010) 6 IA:3 IC:3 3 IA Serous no contralateral ovary, ascites 25 NED 231
IA Endometrioid no para-aortic LNs 31 NED 34
IC Mucinous yes NR 1 DOD 5
Park (2008) 4 IA:2 IC:2 4 IC Endometrioid yes contralateral ovary, uterus, pelvic peritoneum 34 NED 79
IA Mixed yes peritoneum 6 AWD 5
IA Mucinous yes LNs 54 DOD 60
IC Mucinous yes Omentum, mesentery, incisional scar 6 DOD 8
Borgfeldt (2007) 1 IC:1 1 IC Mucinous NR pelvis-abdomen NR DOD <12
Morice (2005) 1 IA:1 IC:1 1 IC Serous yes contralateral ovary, peritoneum, liver 6 DOD 3
Raspagliesi (1997) 2 IA:2 0
Zanetta (1997)
Colombo (1994)
7 NR 1 IA Mucinous yes lung, para-aaortic LNs 12 DOD NR
Total 37 IA:8, IC:7 17 IA:9 IC:6 ovary alone: 0, others: 15
Table 8. Oncologic outcomes after fertility-sparing surgery in patients with stage I non-clear cell  carcinoma grade 3
n, number; CT, chemothepapy during primary treatment; TTR, time to recurrence; FAR, follow-up after recurrence; NED, no evidence of disease; AWD, alive with disease;
DOD, dead of disease; NR, not reported; LNs, lymph nodes.
NED: 4, AWD: 1, DOD: 12
